Xeris Biopharma Holdings Analyst Ratings
Xeris Biopharma Holdings Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 227.38% | HC Wainwright & Co. | $6 → $5.5 | Maintains | Buy |
| 11/10/2023 | 138.1% | Piper Sandler | $5 → $4 | Maintains | Overweight |
| 08/28/2023 | 167.86% | Craig-Hallum | → $4.5 | Initiates Coverage On | → Buy |
| 08/09/2023 | 257.14% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/10/2023 | 257.14% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/09/2023 | 257.14% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 01/27/2023 | 197.62% | SVB Leerink | $6 → $5 | Maintains | Outperform |
| 10/21/2022 | 138.1% | Jefferies | → $4 | Assumes | → Buy |
| 04/28/2022 | 286.9% | Craig-Hallum | → $6.5 | Initiates Coverage On | → Buy |
| 03/16/2022 | 257.14% | Mizuho | $8 → $6 | Maintains | Buy |
| 02/16/2022 | 257.14% | SVB Leerink | $8 → $6 | Maintains | Outperform |
| 12/31/2021 | 376.19% | SVB Leerink | $6 → $8 | Maintains | Outperform |
| 12/31/2021 | 221.43% | HC Wainwright & Co. | $4.25 → $5.4 | Maintains | Buy |
| 11/17/2021 | 257.14% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
| 10/29/2021 | 138.1% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 04/23/2020 | 733.33% | Mizuho | $18 → $14 | Maintains | Buy |
| 02/20/2020 | 971.43% | Mizuho | $22 → $18 | Maintains | Buy |
| 02/18/2020 | 614.29% | Piper Sandler | → $12 | Initiates Coverage On | → Overweight |
| 09/11/2019 | 1209.52% | Mizuho | $27 → $22 | Maintains | Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/13/2023 | 227.38% | HC Wainwright & Co. | 6 美元 → 5.5 美元 | 維護 | 購買 |
| 11/10/2023 | 138.1% | 派珀·桑德勒 | 5 美元 → 4 美元 | 維護 | 超重 |
| 08/28/2023 | 167.86% | Craig-Hallum | → 4.5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/09/2023 | 257.14% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 05/10/2023 | 257.14% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 03/09/2023 | 257.14% | HC Wainwright & Co. | → 6 美元 | 重申 | → 購買 |
| 01/27/2023 | 197.62% | SVB Leerink | 6 美元 → 5 美元 | 維護 | 跑贏大盤 |
| 10/21/2022 | 138.1% | 傑富瑞集團 | → 4 美元 | 假設 | → 購買 |
| 04/28/2022 | 286.9% | Craig-Hallum | → 6.5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 3 月 16 日 | 257.14% | 瑞穗市 | 8 美元 → 6 美元 | 維護 | 購買 |
| 02/16/2022 | 257.14% | SVB Leerink | 8 美元 → 6 美元 | 維護 | 跑贏大盤 |
| 12/31/2021 | 376.19% | SVB Leerink | 6 美元 → 8 美元 | 維護 | 跑贏大盤 |
| 12/31/2021 | 221.43% | HC Wainwright & Co. | 4.25 美元 → 5.4 美元 | 維護 | 購買 |
| 11/17/2021 | 257.14% | SVB Leerink | → 6 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 10/29/2021 | 138.1% | HC Wainwright & Co. | → 4 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 04/23/2020 | 733.33% | 瑞穗市 | 18 美元 → 14 美元 | 維護 | 購買 |
| 02/20/2020 | 971.43% | 瑞穗市 | 22 美元 → 18 美元 | 維護 | 購買 |
| 02/18/2020 | 614.29% | 派珀·桑德勒 | → 12 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 09/11/2019 | 1209.52% | 瑞穗市 | 27 美元 → 22 美元 | 維護 | 購買 |
What is the target price for Xeris Biopharma Holdings (XERS)?
Xeris Biopharma Holdings（XERS）的目標價格是多少？
The latest price target for Xeris Biopharma Holdings (NASDAQ: XERS) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $5.50 expecting XERS to rise to within 12 months (a possible 227.38% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月13日公佈了Xeris Biopharma Holdings（納斯達克股票代碼：XERS）的最新目標股價。該分析公司將目標股價定爲5.50美元，預計XERS將在12個月內上漲至5.50美元（可能上漲227.38％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Xeris Biopharma Holdings (XERS)?
Xeris Biopharma Holdings（XERS）的最新分析師評級是多少？
The latest analyst rating for Xeris Biopharma Holdings (NASDAQ: XERS) was provided by HC Wainwright & Co., and Xeris Biopharma Holdings maintained their buy rating.
Xeris Biopharma Holdings（納斯達克股票代碼：XERS）的最新分析師評級由HC Wainwright & Co. 提供，Xeris Biopharma Holdings維持其買入評級。
When is the next analyst rating going to be posted or updated for Xeris Biopharma Holdings (XERS)?
Xeris Biopharma Holdings（XERS）的下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xeris Biopharma Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xeris Biopharma Holdings was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Xeris Biopharma Holdings的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Xeris Biopharma Holdings的最後一次評級是在2023年11月13日提交的，因此您應該預計下一個評級將在2024年11月13日左右公佈。
Is the Analyst Rating Xeris Biopharma Holdings (XERS) correct?
分析師評級Xeris Biopharma Holdings（XERS）是否正確？
While ratings are subjective and will change, the latest Xeris Biopharma Holdings (XERS) rating was a maintained with a price target of $6.00 to $5.50. The current price Xeris Biopharma Holdings (XERS) is trading at is $1.68, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但Xeris生物製藥控股公司（XERS）的最新評級維持不變，目標股價爲6.00美元至5.50美元。Xeris Biopharma Holdings（XERS）目前的交易價格爲1.68美元，超出了分析師的預期區間。